Meyka Pro banner
Artrya Limited

Artrya Limited Fundamental Analysis (ASX: AYA.AX)

AYA.AX●ASX
HealthcareMedical - Healthcare Information Services
$2.77
$0.04(1.47%)
Australian Market opens in 48h 48m

Artrya Limited Fundamental Analysis (ASX: AYA.AX)

Artrya Limited (ASX: AYA.AX) shows weak financial fundamentals with a PE ratio of -15.92, profit margin of -899.39%, and ROE of -30.04%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position16.43%
PEG Ratio-2.87
Current Ratio15.72

Areas of Concern

ROE-30.04%
Operating Margin-974.79%
We analyze AYA.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -84318.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-84318.4/100

We analyze AYA.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

AYA.AX struggles to generate sufficient returns from assets.

ROA > 10%
-29.51%

Valuation Score

Excellent

AYA.AX trades at attractive valuation levels.

PE < 25
-15.92
PEG Ratio < 2
-2.87

Growth Score

Weak

AYA.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

AYA.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
15.72

Profitability Score

Weak

AYA.AX struggles to sustain strong margins.

ROE > 15%
-3004.36%
Net Margin ≥ 15%
-899.39%
Positive Free Cash Flow
No

Key Financial Metrics

Is AYA.AX Expensive or Cheap?

P/E Ratio

AYA.AX trades at -15.92 times earnings. This suggests potential undervaluation.

-15.92

PEG Ratio

When adjusting for growth, AYA.AX's PEG of -2.87 indicates potential undervaluation.

-2.87

Price to Book

The market values Artrya Limited at 5.77 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.77

EV/EBITDA

Enterprise value stands at -19.09 times EBITDA. This is generally considered low.

-19.09

How Well Does AYA.AX Make Money?

Net Profit Margin

For every $100 in sales, Artrya Limited keeps $-899.39 as profit after all expenses.

-899.39%

Operating Margin

Core operations generate -974.79 in profit for every $100 in revenue, before interest and taxes.

-974.79%

ROE

Management delivers $-30.04 in profit for every $100 of shareholder equity.

-30.04%

ROA

Artrya Limited generates $-29.51 in profit for every $100 in assets, demonstrating efficient asset deployment.

-29.51%

Following the Money - Real Cash Generation

Operating Cash Flow

Artrya Limited generates limited operating cash flow of $-15.84M, signaling weaker underlying cash strength.

$-15.84M

Free Cash Flow

Artrya Limited generates weak or negative free cash flow of $-15.98M, restricting financial flexibility.

$-15.98M

FCF Per Share

Each share generates $-0.10 in free cash annually.

$-0.10

FCF Yield

AYA.AX converts -3.51% of its market value into free cash.

-3.51%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.92

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.87

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.77

vs 25 benchmark

P/S Ratio

Price to sales ratio

16188.04

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.003

vs 25 benchmark

Current Ratio

Current assets to current liabilities

15.72

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.30

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.34

vs 25 benchmark

How AYA.AX Stacks Against Its Sector Peers

MetricAYA.AX ValueSector AveragePerformance
P/E Ratio-15.9231.03 Better (Cheaper)
ROE-30.04%509.00% Weak
Net Margin-89939.29%5163.00% Weak
Debt/Equity0.000.05 Strong (Low Leverage)
Current Ratio15.725.60 Strong Liquidity
ROA-29.51%-155.00% (disorted) Weak

AYA.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Artrya Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ